Treprostinil – USA

Treprostinil – USA

IPR decision (Aug 27, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Final Written Decision
IPR2017-01621
06/21/2017
01/11/2018
Watson Laboratories, Inc.
9,358,240
Terminated-Settled
IPR2017-01622
06/21/2017
01/11/2018
9,339,507
US 9,358,240 (United Therapeutics Corp; Exp: 05/05/2028) –OB listed

1. A method of treating pulmonary hypertension comprising: administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising from 200 to 1000 .mu.g/ml of treprostinil or a pharmaceutically acceptable salt thereof with a pulsed ultrasonic nebulizer that aerosolizes a fixed amount of treprostinil or a pharmaceutically acceptable salt thereof per pulse, said pulsed ultrasonic nebulizer comprising an opto-acoustical trigger which allows said human to synchronize each breath to each pulse, said therapeutically effective single event dose comprising from 15 .mu.g to 90 .mu.g of treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 18 breaths.
US 9,339,507 (United Therapeutics Corp; Exp: 03/10/2028) –OB listed

1. A kit for treating pulmonary hypertension comprising: (i) a formulation comprising 200 to 1000 .mu.g/ml treprostinil or a pharmaceutically acceptable salt thereof; (ii) a pulsed ultrasonic nebulizer comprising an opto-acoustical trigger, configured to (a) aerosolize a fixed amount of treprostinil per pulse, and (b) deliver by inhalation a therapeutically effective single event dose of said formulation, said single event dose comprising 15 .mu.g to 90 .mu.g treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 18 breaths; and (iii) instructions for using the pulsed ultrasonic nebulizer with the formulation to treat a patient with pulmonary hypertension by delivering 15 .mu.g to 90 .mu.g treprostinil or a pharmaceutically acceptable salt thereof in 1 to 18 breaths to the patient in the single event dose.

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2023 Pharma IP Circle. All Rights Reserved